GLP-1 'favorite site' TikToks: what the hype misses

What did @traceystimeline actually say?

Tracy claims that where you inject your GLP-1 medication changes both how many side effects you get and how much weight you lose. After 12 weeks on a GLP-1 and nearly 30 pounds down, she says her stomach gave moderate symptoms and inconsistent weight loss, her thigh gave intense symptoms with weight loss, and her arm became her "holy grail" with the best weight loss and fewest side effects. She also claims she gets better results injecting on the left side of her body versus the right.

These are genuinely interesting observations from someone paying close attention to her own body. But personal experience and pharmacokinetics are two different things, and the science here is messier than her confident take suggests.

Does the science back this up?

Partially, yes. Injection site does affect drug absorption, but the evidence does not support the idea that one site consistently produces more weight loss than another in the way Tracy describes.

The prescribing information for semaglutide (Ozempic, Wegovy) does note that the abdomen, thigh, and upper arm are all approved injection sites, with the abdomen showing slightly faster absorption than the thigh or arm. A 2020 pharmacokinetic study by Kapitza et al. published in the Journal of Clinical Pharmacology found that subcutaneous injection site can influence absorption rate for GLP-1 receptor agonists, but the differences in area under the curve, which is a proxy for total drug exposure, were not clinically dramatic.

The idea that more muscle and less fat in the thigh means less medication absorbed is plausible but oversimplified. Subcutaneous injections are meant to go into fat, not muscle. If someone has less subcutaneous fat on their thigh, absorption could vary. But this does not translate cleanly into "more or less weight loss" from that site.

Side effect differences by site are also reported anecdotally in the GLP-1 community, but there is no robust clinical trial data showing that the upper arm produces fewer GI side effects than the abdomen. The nausea and GI symptoms from semaglutide are driven by central and peripheral GLP-1 receptor activity in the gut and brain, not primarily by injection site.

What did they get wrong (or right)?

Tracy gets credit for trying all three approved sites and tracking her response. That is actually good practice. Rotating injection sites is recommended to avoid lipohypertrophy, a buildup of fatty tissue from repeated injections in the same spot that can impair absorption.

Where she goes wrong is the causal framing. She says she "doesn't really lose weight" when injecting on her right side versus her left. This is almost certainly coincidence or confirmation bias, not pharmacology. There is no physiological mechanism by which the left versus right side of the body would produce meaningfully different semaglutide absorption or weight loss outcomes. The body's lymphatic and vascular systems are roughly symmetrical for subcutaneous drug uptake.

Her doctor's comment that people "usually don't have as much weight loss" in the thigh is not well-supported by published data either. It may reflect that patient anecdote in-clinic, but it should not be taken as established clinical fact. To Tracy's credit, she frames it as her doctor's "theory," not gospel.

The claim that intense symptoms equal more weight loss is also shaky. GI side effects from GLP-1s are not a marker of efficacy. They are a marker of tolerability issues. People who have fewer side effects are not necessarily losing less weight.

What should you actually know?

Injection site rotation matters, but not for the reasons this video implies. Rotating between the abdomen, thigh, and upper arm is recommended by clinical guidelines to prevent tissue damage and maintain consistent absorption over time, not to optimize weight loss by picking a "favorite" site.

If you are finding that one site gives you fewer side effects, that is a reasonable reason to prefer it, and worth telling your prescriber. But attributing your weekly scale number to where you injected is not supported by evidence. Weight loss on semaglutide or tirzepatide is driven by dose, adherence, diet, activity, and individual metabolic factors, not which arm you used.

Tracy's 29.8-pound loss in 12 weeks is within the range seen in clinical trials, though on the higher end. The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) showed average weight loss of around 14.9% of body weight over 68 weeks. Individual results vary substantially. Her results are real. The injection-site explanation for them is speculative.

If you are struggling with side effects, talk to your prescriber about dose titration timing before experimenting with injection sites as a workaround. That is the more evidence-based lever to pull.